Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the "Investors” section of the company’s website at www.alnylam.com.Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation at the 2009 Annual Credit Suisse Healthcare Conference will be webcast live via the internet , on Friday, November 13, 2009 at 8:30 a.m. MST, 6:30 a.m. EST.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter 2009 financial results.

CEL-SCI Corporation (NYSE:CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology.

Clinical Data, Inc. (NASDAQ:CLDA) announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.Compugen Ltd. (NASDAQ:CGEN) announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes the most common form of diabetes.Commonwealth Biotechnologies, Inc. (NASDAQ:CBTE) is pleased to announce it has completed the divestment of the assets (excluding land and buildings) of its bioanalytical and genetic testing business units, CBI Services and Fairfax Identity Laboratory (FIL) for a cash consideration and an ongoing lease commitment for 5 years.EpiCept Corporation (Nasdaq:EPCT) announced Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.Global Health Ventures Inc. (OTC:GHLV), or the "Company" a Specialty Pharma is pleased to announce it has completed the prototype manufacturing of the drug "X-Excite" Global's male enhancement drug.Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, announced it has committed to provide Labcyte, Inc. (www.labcyte.com) $5.5 million in credit facilities.Lannett Company, Inc. (NYSE:LCI) reported financial results for the fiscal 2010 first quarter ended September 30, 2009.Mentor Capital, Inc.'s (OTC:MNTR) major investee, Quantum Immunologics, reported significant advances in its recent Quarterly Conference Call. Monsanto Company (NYSE:MON) and Pfizer Inc (NYSE: PFE) announced they have entered into an agreement for Monsanto to acquire Pfizer's Chesterfield Village Research Center located in Chesterfield, Mo.OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced OSI Management will present at the Lazard Healthcare Conference in New York, NY on Tuesday, November 17, 2009 at 8:55am (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.Repros Therapeutics (Nasdaq:RPRX) announced financial results for the third quarter ended September 30, 2009.SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.Walgreens (NYSE:WAG)(NASDAQ:WAG), Monthly total increases 185 percent over year ago E-prescribing promotes goals of health care reform as it lowers cost and improves adherence to drug therapy Federal stimulus package further bolsters electronic prescribing.Walgreens (NYSE:WAG)(NASDAQ:WAG), President and CEO Greg Wasson will present during the Morgan Stanley Global Consumer and Retail Conference in New York on Thursday, Nov. 19, 2009 at approximately 8:20 a.m. EST.Yasheng Group (OTC:YHGG), announced an agreement between Yasheng Group's majority shareholder Yasheng Group BVI and Yasheng ECO Trade Corp wherein Yasheng Eco Trade was to acquire 75,000,000 shares of Yasheng Group has been terminated due to a clause in the agreement that either party could terminated if the acquisition was not concluded by the end of September 2009.

Shares of EpiCept (NASDAQ: EPCT) are ready to move as speculation about coming news had shares trading up more than 21% on Wednesday. People are starting to take notice of this small biotech company with big ambitions.

 

Key News

The Company possesses an approved cancer product and a deep and balanced pipeline of three major clinical product candidates:

 

Ceplene(R) - approved in the European Union for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission; AML is the most common form of leukemia in adults. In June 2009 EpiCept launched a Named Patient Program for Ceplene(R) in Europe and certain other markets through a partnership with IDIS. Drug inventory has been manufactured and shipped to the European Union for use by IDIS and in preparation for the commercial launch. Currently there are no other effective medical-based therapies for AML patients.

 

EpiCeptTM NP-1 - a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affect more than 15 million people in the U.S. alone. In January 2009 EpiCept reported positive top line results from a 360-patient Phase IIb trial of NP-1 in patients with post-herpetic neuralgia. In this trial NP-1 achieved statistically significant pain relief as compared to placebo and was not statistically different in pain relief to the market leader Gabapentin, yet had fewer CNS side effects.

 

Crinobulin (EPC2407) - a vascular disruption agent which has demonstrated potent anti-tumor activity in both preclinical and early clinical studies. In preclinical in vitro and in vivo studies, Crinobulin has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. In May 2009 EpiCept announced the completion of a Phase Ia study that determined Crinobulin's maximum tolerated dose and provided evidence of clinical symptomatic activity and radiographic evidence of efficacy in end stage patients. The Company is making preparations to initiate a Phase Ib trial for the compound in combination with other chemotherapeutic agents.

 

Azixa(TM) - a compound discovered by EpiCept and licensed to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement. Myriad is currently conducting Phase II trials for Azixa and intends to disclose the outcome of at least one of their ongoing Phase II Azixa trials at the November 2009 meeting of the American Association for Cancer Research (AACR). If successful, these results could lead to Phase III registration trials for the compound, which would trigger a milestone payment to EpiCept.

 

The recent spike in volume and share price may be attributed to one or more of these upcoming catalysts:

 

On 8/05/2009 EpiCept filed a New Drug Submission (NDS) for approval of Ceplene with Canada. Health Canada typically accepts or refuses an NDS and designates review status within 45 days of filing. Investors are anticipating news in regards to this NDS to be released shortly. Sources at the company say that investors should expect a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Ceplene towards the end of 2009. Contingent upon discussions with the FDA. Investors are anticipating the release of EpiCept NP-1 updated stage 3 clinical trials. Said announcement could take place next week (see #5 below) Scheduled Azixa update in November 2009 Next week, on 9/09/2009- EpiCept  presentation at the Rodman and Renshaw 11th Annual Global Investment Conference which attracts over 3500 investors including mutual funds, hedge funds and various institutional investors.

 

A strong pipeline combined with numerous upcoming events could continue to propel this stock higher in the coming weeks.

 

 

Disclosure: Long EPCT

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

EpiCept Corporation (Nasdaq:EPCT) announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.

Allergan, Inc. (NYSE:AGN) announced the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%.

Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Aventis Group, and Keith H. Wells, a senior member of the Biologics Consulting Group and former director of vaccine development for The Salk Institute, to the board.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced it plans to report third quarter 2009 results on Monday, November 9. SciClone will host a conference call to give a business and product update at 8:30 am ET that day.

EpiCept Corporation (Nasdaq:EPCT) announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced veteran public company board member and dental executive Gregory D. Waller has been named to its Board of Directors, effective immediately.

Shire plc (NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced an overview of the Company’s business strategy will be presented at the 2009 BIOCOM Investor Conference on Tuesday, October 27, 2009 at 9:30am Pacific Time.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the Company will report third quarter 2009 financial results following the close of the U.S. financial markets on Monday, November 9, 2009.

NanoViricides, Inc. (OTC:NNVC), reports the Company is well financed and its game changing anti-viral drug development programs are progressing successfully.

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. (NASDAQ:CGEN) project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

Antigenics (NASDAQ:AGEN) announced the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA. Data were presented in Sunrise Session #6: Immunotherapy: Current Status of Clinical Trials on Saturday, October 24.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced it plans to report third quarter 2009 results on Monday, November 9.

Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) announced Richard W. Pascoe, Somaxon’s president and chief executive officer, will present a company overview at the Oppenheimer 20th Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Wednesday, November 4th at 4:30 P.M. Eastern Time.

Rexahn Pharmaceuticals, Inc. (NYSE:RNN) announced it has completed its previously announced Registered Direct Offering of common stock and warrants.

Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics,  announced Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET.

Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company's TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

AVI BioPharma, Inc. (NASDAQ:AVII), a developer of RNA-based drugs, presented an update on preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of exon skipping AVI-4658 in patients with Duchenne muscular dystrophy (DMD) at the 7th Annual Action Duchenne Conference in London, UK.

Dyadic International, Inc. (OTC:DYAI) announced financial results for the first and second quarters of 2009 as well as for the years ended December 31, 2008 and 2007.

AMRI (NASDAQ:AMRI) announced it will issue third quarter financial results before the opening of the market on Monday, November 9, 2009. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. EST.

Cannabis Science Inc. (OTC:CBIS) an emerging pharmaceutical cannabis company, is urging that US government recognize that phytocannabinoid pharmaceutical products can help reduce Adult Respiratory Distress Syndrome (ARDS)-associated deaths from both the Avian and Swine Influenza infections, as President Obama declares a national emergency.

Fero Industries, Inc. (OTC:FROI) is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) reported additional data from a Phase 3 study supporting the efficacy of GATTEX™ (teduglutide) in   patients with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

CEL-SCI Corporation (AMEX:CVM) announced it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common stock.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announces the 2009 American College of Gastroenterology (ACG) Annual Scientific Meeting will be the venue for 13 presentations describing the investigation of the Company’s bacterial-related disease, inflammatory bowel disease and bowel cleansing product lines.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced it plans to report third quarter 2009 financial results on Thursday, November 5, 2009, following the close of market.

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reviewed recent business and clinical progress and reported consolidated financial results for the quarter ended September 30, 2009.

SuperGen, Inc. (NASDAQ:SUPG) reported financial results for the third quarter and nine months ended September 30, 2009.

Microfluidics International Corporation (OTC:MFLU) announced it has received a $1.0 million secured revolving line of credit from Webster Bank, N.A.

EastBridge Investment Group (OTC:BIG) announced its CEO, Keith Wong, has attended a land acquisition signing ceremony in Jiyuan, Henan for Alpha Green Energy Limited.

Inhibitex, Inc. (NASDAQ: INHX) announced a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

EpiCept Corporation (Nasdaq:EPCT) announced a Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market.

GenVec, Inc. (Nasdaq:GNVC) announced Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the Merriman Curhan Ford's 6th Annual Investor Summit on Tuesday, November 10, 2009 at 9:20 am EST at Sofitel Hotel in New York, NY.

Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) announced its third quarter 2009 financial results. For the three months ended September 30, 2009, Enzon reported a net income of $0.1 million or break-even on a diluted per-share basis, as compared to a net loss of $2.0 million or $0.05 on a diluted per-share basis for the third quarter of 2008.

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Investor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) reported results for the quarter ended September 30, 2009.

Aetna (NYSE:AET) is providing free electronic roster billing for pharmacies and other non-traditional providers to use when submitting claims for the administration of the H1N1 flu vaccine.

Stem Cell Therapy International Inc. (OTC:SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced they have entered into a definitive agreement for up to a $5 million investment commitment with Socius Life Science Capital Group, LLC.The Company's plan is to have funds available no later than December 31, 2009 and use the proceeds for various growth initiatives, including the launch of its stem cell based facial cream, the initiation of clinical trials, maintaining and advancement of current GMP facility as well as ongoing working capital and general corporate purposes.

NanoLogix, Inc. (OTC:NNLX), announces the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU.

Sinovac Biotech Ltd. (NYSE:SVA), a leading developer and provider of vaccines in China, announced it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market.

Solos Endoscopy, Inc. (OTC:SNDY) is pleased to announce the Company has received purchase orders for its MammoView(TM) line of surgical endoscopy instruments from various hospitals under Catholic Health Initiatives, Littleton, CO.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.

Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced Robert Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern Time at the Lazard Capital Markets 6th Annual Healthcare Conference at the St Regis Hotel in New York City.

Merck & Co., Inc. (NYSE:MRK) and Schering-Plough Corporation (NYSE:SGP) announced they will complete their merger shortly after 4:00PM ET.

Advanced Cell Technology, Inc. (OTC:CTC) announced its Chief Executive Officer, William Caldwell, IV, presented at the BIO Europe Conference being held in Vienna, Austria.

Catalyst Health Solutions, Inc. (NASDAQ:CHSI), a pharmacy benefit management company, announced its financial results for the third quarter ended September 30, 2009.

Optigenex Inc. (OTC:OPGX), has unveiled a new information web page www.optigenex.com designed to connect with prospective corporate customers and partners in the wellness and personal care industries.

Walgreens (NYSE:WAG) executive vice president and chief financial officer Wade Miquelon will present during the Credit Suisse Annual Healthcare Conference in Phoenix on Thursday, Nov. 12, 2009 at approximately 10 a.m. MST (noon EST).

BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) announced the Company plans to release its financial results for the three and nine months ended September 30, 2009, on Thursday, November 5, 2009 after the close of the market.

BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced the launch of the Diolase 10™ Diode Laser for therapeutic applications, including temporary pain relief.

Aethlon Medical, Inc. (OTC:AEMD) announced it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

ULURU Inc. (NYSE:ULU) announced it has scheduled a conference call to discuss the third quarter ended September 30, 2009 financial results and provide a general business update on Tuesday, November 17, 2009 at 9:00 a.m. Eastern Time.

CNS Response, Inc. (OTC:CNSO) reported the results of a landmark study presented by Charles DeBattista, D.M.H, M.D., at the U.S. Psychiatric and Mental Health Congress.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.

Viriathus Research LLC, an independent research firm, issued an Update Report for Viralytics Limited (OTC: VRACY), a biotechnology company which is developing therapies and drugs for the treatment of cancer in Australia.

Affymax, Inc. (Nasdaq:AFFY) announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009.

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Inventor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.

Walgreens (NYSE:WAG), the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, will begin offering H1N1 injectable vaccines at 18 pharmacies throughout Salt Lake County Thursday.

Below is a list of the companies that made news in the healthcare sector on Thursday, November 05, 2009.

 

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

 

CVS Caremark (NYSE:CVS) announced the appointment of David M. Denton to the new role of Executive Vice President and Chief Financial Officer, effective January 1, 2010. Denton will succeed David Rickard who announced in February of this year his intention to retire as CFO.

 

NovaDel Pharma Inc. (NYSE:NVD), announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

 

NexMed, Inc. (Nasdaq:NEXM), a developer of innovative topical products based on the NexACT® technology, announced management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST.

 

IMS Health (NYSE:RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital (“TPG”) and the CPP Investment Board (“CPPIB”) in a transaction with a total value of $5.2 billion, including the assumption of debt.

 

StemCells, Inc. (NASDAQ:STEM) reported financial results for the third quarter ended September 30, 2009.

 

EpiCept Corporation (Nasdaq:EPCT) announced it will host a conference call to discuss third quarter 2009 operating and financial results on Tuesday, November 10, 2009 at 9:00 a.m. EST. The call will follow the release of these financial results earlier in the day at 12:01 a.m. EST.

 

BMP Sunstone Corporation (Nasdaq:BJGP) announced the Company plans to release third quarter 2009 financial results on Monday, November 9, 2009, after the market closes.

 

Transgenomic, Inc. (OTC:TBIO) announces the following Webcast:  What: Transgenomic, Inc. Third Quarter 2009 Earnings Release Conference Call When: Thursday, November 5, 2009 @ 5:00 p.m. Eastern.

 

Unilife Medical SolutionsLimited (OTC:UNIFF) wishes to advise shareholders of the release of a Finance News Network interview conducted recently with Unilife CEO Alan Shortall.

 

Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced its financial results for the third quarter ended September 30, 2009.

 

VIVUS, Inc. (Nasdaq:VVUS) announced Leland Wilson, chief executive officer, will present an overview of the company at Merriman Corhan Ford's 6th Annual Investor Summit.

 

MAP Pharmaceuticals, Inc. (Nasdaq:MAPP) announced financial results for the third quarter ended September 30, 2009.

 

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford’s 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.

 

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse’s 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November 12, 2009.

 

Levi & Korsinsky is investigating the Board of Directors of IMS Health Inc. (NYSE:RX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm TPG and the CPP Investment Board of Toronto ("CPP").

 

OncoVista Innovative Therapies, Inc. (OTC:OVIT) reported strong growth in revenue, in the second quarter of 2009.

 

CVS Caremark Corporation (NYSE:CVS) announced its Board of Directors has approved a new share repurchase program for up to $2.0 billion of its outstanding common stock.

 

Emergent BioSolutions Inc. (NYSE:EBS) announced its financial results for the third quarter and nine months ended September 30, 2009.

 

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, announced financial results for the quarter ended September 30, 2009.

 

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, reported its financial results for the third quarter ended September 30, 2009.

 

Life Sciences Research, Inc. (NYSE:LSR) announced financial results for the three and nine months ended September 30, 2009.

 

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, announced financial results for the third quarter ended September 30, 2009.

 

S3 Investment Company, Inc. (OTC:SIVC) issued comment from Chairman and CEO Jim Bickel regarding the recent progress of its wholly owned subsidiary businesses, Redwood Capital and Redwood Medical, both of which operate in the China market.

 

Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ® to include long-term data from the CASTLE Study.